September 6, 2016
(The Washington Post) – What eventually saved her, though, was an experimental transplant using stem cells from the blood of a baby’s umbilical cord, an approach that can be used without perfectly matching blood types. This therapy and another — haploidentical transplantation, which uses bone-marrow cells that are only half-matched to a patient — have revolutionized the treatment of blood cancers in the past few years. Every biological child is a half-match for a parent, and vice versa. “Many patients who previously died for lack of a match are now cured of their underlying malignancy,” said Richard Jones, director of the bone-marrow transplant program at Johns Hopkins Kimmel Cancer Center.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.